Availability of medicines in the European Union: Results from the EURO-Medicines project

European Journal of Clinical Pharmacology

Volumn 57, Issue 5-6, 2001, Pages 441-446

  Wang, Qinghua ^a   Wu, Yuanhong ^a   Aerts, Tony ^a   Slegers, Herman ^a   Clauwaert, Julius ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Europe; Medicines; Regulation

Indexed keywords

ANTINEOPLASTIC AGENT; CARDIOVASCULAR AGENT; DRUG; GASTROINTESTINAL AGENT; ANTIINFECTIVE AGENT; ANTIPARASITIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DERMATOLOGICAL AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NOOTROPIC AGENT; PIRACETAM; PSYCHOSTIMULANT AGENT; VASODILATOR AGENT;

ARTICLE; CULTURAL ANTHROPOLOGY; DENMARK; DRUG MARKETING; EUROPE; EUROPEAN UNION; GERMANY; HISTORY; ITALY; ORGANIZATION; PRIORITY JOURNAL; DRUG BIOAVAILABILITY; DRUG CONTROL; DRUG INDUSTRY; POLICY; PUBLICATION; SCANDINAVIA;

DATA COLLECTION; DIRECTORIES; DRUG THERAPY; DRUG UTILIZATION; EUROPE; EUROPEAN UNION; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 85017228435     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280100345     Document Type: Article

References (16)

1. EMEA and the new pharmaceutical procedures for Europe
2. Prescribing in Europe-forces for change
3. Pharmaceutical prescriptions in four European countries
4. The drug market in four European countries
5. Council Regulation (EEC) No 2309/93 of 22 July 1993 laying down community procedures for the authorization and supervision of medicinal products for human and veterinary use and establishing a European Agency for the Evaluation of Medicinal Products
6. Council Directive 89/105/EEC of 21 December 1988 relating to the transparency of measures regulating the prices of medicinal products for human use and their inclusion in the scope of national health insurance systems
7. Council Directive 92/26/EEC of 31 March 1992 concerning the classification for the supply of medicinal products for human use
8. An attempt to save money by using mandatory practice guidelines in France
9. Cultural shift in Italy's drug policy
10. Discrepancy remains in pharmaceutical prescriptions in four European countries
11. Single European currency and Monetary Union. Macroeconomic implications for pharmaceutical spending